Cross, N. C. P.4; White, H. E.4; Colomer, D.4; Ehrencrona, H.4; Foroni, L.4; Gottardi, E.4; Lange, T.5; Lion, T.4; Polakova, K. M.4; Dulucq, S.4; Martinelli, G.4; Leibundgut, E. O.4; Pallisgaard, N.6; Barbany, G.4; Sacha, T.4; Talmaci, R.4; Izzo, B.4; Saglio, G.4; Pane, F.4; Muller, M. C.7; Hochhaus, A.4
1 Department of Biology, Faculty of Science, SDU2 Department of Biochemistry, Institute of Regional Health Research, Det Sundhedsvidenskabelige Fakultet, SDU3 Department of Political Science and Public Management, Faculty of Business and Social Sciences, SDU4 unknown5 Department of Biology, Faculty of Science, SDU6 Department of Biochemistry, Institute of Regional Health Research, Det Sundhedsvidenskabelige Fakultet, SDU7 Department of Political Science and Public Management, Faculty of Business and Social Sciences, SDU
Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.
Journal review article
Leukemia, 2015, Vol 29, Issue 5, p. 999-1003
MINIMAL RESIDUAL DISEASE POLYMERASE-CHAIN-REACTION HARMONIZING CURRENT METHODOLOGY CHRONIC MYELOGENOUS LEUKEMIA BCR-ABL TRANSCRIPTS INTERNATIONAL SCALE CANCER PROGRAM PCR IMATINIB STANDARDIZATION